Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 8/20 | 0.44 |
| ▸ | BCHE | P06276 | 4/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038530 | 0.91 | ACHE (0.47) | ACHEBCHECD274KDM4ETMEM97 | |
| SCHEMBL5992516 | 0.90 | KDM4E (0.47) | ACHEBCHECD274KDM4ETMEM97 | |
| SCHEMBL1035892 | 0.89 | SLC2A1 (0.49) | SLC2A1ACHEBCHESIGMAR1ALDH1A1 | |
| SCHEMBL1032923 | 0.87 | ACHE (0.43) | ACHEBCHECD274KDM4ESMN1; SMN2 | |
| SCHEMBL1036964 | 0.86 | MEN1 (0.45) | ACHEBCHECD274KDM4ETMEM97 | |
| SCHEMBL1037998 | 0.86 | ACHE (0.42) | ACHEBCHECD274 | |
| SCHEMBL1038386 | 0.86 | TMEM97 (0.47) | SLC2A1ACHEBCHECD274KDM4E | |
| SCHEMBL1035600 | 0.86 | SMN1; SMN2 (0.45) | ACHEBCHECD274SMN1; SMN2ALDH1A1 | |
| SCHEMBL1036749 | 0.85 | KDM4E (0.48) | ACHEBCHECD274KDM4EALDH1A1 | |
| SCHEMBL1033735 | 0.85 | KDM4E (0.44) | SLC2A1ACHEBCHECD274KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831173-B1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-26 | — | — | EP | disclosed |
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | HRH3, HRH4, HRH1 | SLC2A1 376/4885ACHE 2621/4885BCHE 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.